upgrad buy pt ahead
messag two new program aatd fsg progress earli clinic
trial plu recent bd ad tech think continu drive long-term
product think posit well beyond upgrad
buy neutral assign pt ad probability-adjust
revenu fsg aatd program model
recent progress cf encourag though still believ fulli
reflect current level hat execut cf side thing
term progress launch prior medicin well earlier-than-
expect trikafta approv expect one launch well drive top-
bottom-lin growth forseeabl futur also think help point leverag
on-going ex-u reimburs discuss alreadi seen progress
said alreadi reflect model assum peak cf sale
line consensu
think upsid valuat come earli stage pipelin
final start come focu crux prior neutral rate
lack visibl earli stage pipelin hard us give credit
program quit know give credit cours year
learn earlier stage program name aatd fsg
enabl us think model ad revenu model probability-
adjust credit well dilig effort updat deep dive
deck earli stage pipelin
dig approach aatd fsg
encourag ahead initi data small molecul
corrector expect move poc studi next year aatd patient
zz mutat aatd compani also second investig corrector
current detail aatd mechan see
takeaway recent kol call fsg expect finish studi
year success move poc studi takeaway
recent fsg focus kol call
also encourag recent bd activ ad new tech
capabl toolbox gene therapi move meaning
gene edit space acquisit exon expand preclin
effort dmd time compani also hire viral vector expert
dr john gray build intern vector capabl establish genet therapi
research boston encourag invest addit exist
relationship crsp think compani posit well within
genet medicin space must compani rare diseas space view
cell therapi diabet recent acquir semma therapeut
compani gener posit preclin poc off-the-shelf cell therapi
type diabet deal initi took us guard end posit
inclin toward deal like valid provid similar allo approach
unlik pain could still commerci specialti salesforc also note
program fairli advanc semma previous guid enter
clinic though yet confirm chang timelin info
cell therapi landscap see note recent kol call
earlier-stag deal posit compani continu innov
collabor may also signal compani scientif
expans use kymera target protein degrad drug discoveri platform seriou
page analyst certif import disclosur
diseas deal arbor biotechnolog ribometrix also
expand horizon research develop
model updat ad aatd fsg program model base
dcf valuat arriv pt upgrad recommend buy
forecast probability-weight revenu expens assum
discount rate termin growth rate po cf tripl therapi po
gene therapi po aatd fsg program po
compani report guggenheim secur llc research
page analyst certif import disclosur
base dcf valuat arriv pt upgrad recommend buy forecast probability-weight revenu
expens assum discount rate termin growth rate po cf tripl therapi po
gene therapi po aatd fsg program po program
suscept risk appli entir biotech industri includ develop regulatori commerci
manufactur financ ip risk specif includ
clinic risk delay clinic trial initi unexpect safeti issu efficaci lower expect
regulatori risk clinic trial ultim success possibl vrtx medicin approv global regulatori
agenc given novelti technolog agenc may requir addit long-term data could delay potenti approv
ip risk crispr landscap rapidli evolv guarante access new develop
technolog emerg space
competitor risk technolog wide follow public media possibl news
technolog unrel /crsp could lead downsid share
page analyst certif import disclosur
mm except per share data
factset consensu
total incom expens net
incom tax
loss attribut non-controlling interest
net incom attribut
non-gaap net incom attribut
factset consensu
gaap cog tot prod sale
 tot revenu
sg tot revenu
compani report guggenheim secur llc estim
page analyst certif import disclosur
